Conversely, a separate large dataset of 1042 MDS patients found no difference in overall survival for either mutation compared to the wild‐type population (OS: IDH1 22.2 months, IDH2 21.0 months, IDHwt 21.1 months). Here, IDH2 is linked to myelodysplastic syndrome.